Ferl GZ, Theil FP, Wong H. Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications. Biopharm Drug Dispos. 2016 Mar;37(2):75-92. doi: 10.1002/bdd.1994. PMID: 26461173.
Liu X, Wong H, Scearce-Levie K, Watts RJ, Coraggio M, Shin YG, Peng K, Wildsmith KR, Atwal JK, Mango J, Schauer SP, Regal K, Hunt KW, Thomas AA, Siu M, Lyssikatos J, Deshmukh G, Hop CE. Mechanistic pharmacokinetic-pharmacodynamic modeling of BACE1 inhibition in monkeys: development of a predictive model for amyloid precursor protein processing. Drug Metab Dispos. 2013 Jul;41(7):1319-28. doi: 10.1124/dmd.112.050864. Epub 2013 Apr 12. PMID: 23584887.
Wong H, Choo EF, Alicke B, Ding X, La H, McNamara E, Theil FP, Tibbitts J, Friedman LS, Hop CE, Gould SE. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res. 2012 Jul 15;18(14):3846-55. doi: 10.1158/1078-0432.CCR-12-0738. Epub 2012 May 30. PMID: 22648270.
Wong H, Vernillet L, Peterson A, Ware JA, Lee L, Martini JF, Yu P, Li C, Del Rosario G, Choo EF, Hoeflich KP, Shi Y, Aftab BT, Aoyama R, Lam ST, Belvin M, Prescott J. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res. 2012 Jun 1;18(11):3090-9. doi: 10.1158/1078-0432.CCR-12-0445. Epub 2012 Apr 10. PMID: 22496205.
Wong H, Alicke B, West KA, Pacheco P, La H, Januario T, Yauch RL, de Sauvage FJ, Gould SE. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation. Clin Cancer Res. 2011 Jul 15;17(14):4682-92. doi: 10.1158/1078-0432.CCR-11-0975. Epub 2011 May 24. PMID: 21610148.
"Drug Discovery of the Year Award." Graham RA, Wong H, Hop C, Gould S, de Sauvage F, Low J, Colburn D, Jin J, Dresser M, Joshi A, Lum B, Chang I, Mackey H, Roth I. The British Pharmacological Society. December 19, 2012.
"Physiologically-based Pharmacokinetic Modeling: Overview and Applications." Wong H. Pharmaceutical and BioScience Society – San Francisco Bay Workshop: Physiologically Based PK (PBPK) Modeling: Overview, Applications, Regulatory Opinions and Software Demo, Foster City, CA, USA. April 24, 2015.
"The Role of Preclinical Pharmacokinetic/ Pharmacodynamic Analysis in the Discovery and Development of Vismodegib." Wong H. Applied Pharmaceutical Analysis - India 2015 organized by the Boston Society, Mumbai, India. February 22-25, 2015.
"Translational Pharmacokinetic/ Pharmacodynamic Analysis as a Tool to Discover New Medicines." Wong H. 7th International Symposium on Drug Metabolism and Pharmacokinetics organized by the National Institute of Pharmaceutical Education and Research S.A.S. Nagar, NIPER, Mohali, India. February 18-21, 2015.
"From Mouse to Man and Back: Translational Pharmacokinetic-Pharmacodynamic Modeling in Oncology." Wong H. 2013 Gordon Research Conference on Drug Metabolism (Applications of PK-PD and TK-TD in Drug Discovery and Development Session), Holderness, NH, USA. July 7-12, 2013.
"Improving the Predictive Power of Preclinical Tumor Models Through Translational Pharmacokinetic-Pharmacodynamic Analysis." Wong H. CPSA Shanghai 2013: Reviving Pharmaceutical R&D with Translational Science, Regulatory Efficiency, and Innovative Models, Shanghai, China. April 24-27, 2013.
Dr. Harvey Wong is an Associate Professor of Pharmacokinetics in the Faculty of Pharmaceutical Sciences. He obtained his B.Sc. in pharmacy, and Ph.D. in pharmacokinetics and biopharmaceutics at UBC. Following graduation, Dr. Wong was employed in pharmaceutical industry at the DuPont Pharmaceuticals Company, Bristol-Myers Squibb, and most recently at Genentech in the areas of oncology, neuroscience, and immunology. At Genentech, he served as a research project team leader, a non-clinical development team leader, and gained extensive experience in regulatory filings. Most notably, Dr. Wong was part of the team involved in the development of vismodegib (Erivedge®), the first in class hedgehog pathway inhibitor, which was awarded the "Drug Discovery of the Year" award in 2012 by the British Pharmacological Society.
Dr. Wong's expertise is in drug discovery and development strategies with a specialization in ADME, pharmacokinetics, and modeling and simulation (translational PK/PD analysis, systems pharmacology, and physiologically based pharmacokinetic modeling). He currently chairs the PK/PD Discussion Group for the IQ Consortium and serves on the Editorial Board of Biopharmaceutics and Drug Disposition.
Dr. Harvey Wong's research interests include applications of translational modeling and simulation techniques to optimize drug dose and regimen for new therapeutics, and to better understand emergence of cancer tumor drug resistance.